Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 71Neoplasms 70Lung Neoplasms 29Prostatic Neoplasms 26Head and Neck Neoplasms 22Colorectal Neoplasms 19Uterine Cervical Neoplasms 17Ovarian Neoplasms 13Neoplasm Metastasis 13Motor Activity 13Fatigue 11Endometrial Neoplasms 11Colonic Neoplasms 11Brain Neoplasms 11Pain 10Carcinoma, Non-Small-Cell Lung 10Multiple Myeloma 9Melanoma 9Rectal Neoplasms 8Leukemia 8Gastrointestinal Neoplasms 8Smoking Cessation 7Pancreatic Neoplasms 7Lymphoma 7Depression 7cyclopia sequence 6Esophageal Neoplasms 6Carcinoma, Renal Cell 6Advanced Cancer 6Uterine Neoplasms 5

Interventions

Everolimus 17lutetium Lu 177 dotatate 7Octreotide 7pasireotide 6lanreotide 6gallium Ga 68 dotatate 5Temozolomide 5Sunitinib 5Positron Emission Tomography Computed Tomography 5surufatinib 4pembrolizumab 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroendocrine Tumors × Surveys and Questionnaires × Clear all
NCT03289741 2025-05-09

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Memorial Sloan Kettering Cancer Center

Phase 4 Completed
51 enrolled 10 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡